Evolving immunotherapeutic solutions for triple-negative breast carcinoma

2024-11-1

Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape

2024-11-1

Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications

2024-11-1

Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer

2024-9-1

Liquid biopsy: An arsenal for tumour screening and early diagnosis

2024-9-1

Overview of BH3 mimetics in ovarian cancer

2024-9-1

Locally advanced and metastatic endometrial cancer: Current and emerging therapies

2024-9-1

Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

2024-9-1

Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma

2024-9-1

HER-2 directed therapies across gastrointestinal tract cancers – A new frontier

2024-9-1

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

2024-9-1

Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review

2024-9-1

The active involvement of patients in oncology research

2024-9-1

Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation

2024-9-1

Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes

2024-9-1

Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes

2024-9-1

The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials

2024-9-1

Long road towards effective HER3 targeting in breast cancer

2024-9-1

Extracellular vesicles and the “six Rs” in radiotherapy

2024-9-1

Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review

2024-9-1

Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck

2024-9-1

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes

2024-9-1

Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors

2024-9-1

Brachytherapy and external beam radiation in the management of primary penile cancer – Game changer for organ preservation?

2024-9-1

Bone complications of cancer treatment

2024-9-1

Editorial Board

2024-9-1

Precision medicine for multiple myeloma: The case for translocation (11;14)

2024-9-1

Challenges and future perspectives for the use of temozolomide in the treatment of SCLC

2024-9-1

Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature

2024-9-1

Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies

2024-9-1

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development

2024-9-1

Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer

2024-8-30

Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives

2024-8-22

Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review

2024-8-1

Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review

2024-8-1

Early-Onset colorectal Cancer: From the laboratory to the clinic

2024-8-1

Hormone receptor-positive early breast cancer in young women: A comprehensive review

2024-7-14

Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act

2024-7-11

Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials

2024-7-3

Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review

2024-7-2

Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers

2024-7-1

The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer

2024-7-1

Editorial Board

2024-7-1

The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer

2024-7-1

Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implications

2024-7-1

Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration

2024-7-1

Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer

2024-7-1

Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?

2024-7-1

The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer

2024-7-1

Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis

2024-7-1